Status:
COMPLETED
Efficacy and Safety of Pactimibe in Patients With Atherosclerosis
Lead Sponsor:
Sankyo Pharma Gmbh
Conditions:
Atherosclerosis
Eligibility:
All Genders
30-75 years
Phase:
PHASE2
Brief Summary
The effect of pactimibe on the reduction of atherosclerosis in the carotid artery will be assessed using carotid ultrasound
Eligibility Criteria
Inclusion
- Increased cardiovascular risk (i.e. history of myocardial infarction, stroke, diabetes mellitus, left ventricular hypertrophy)
- Intima-media thickness greater than or equal to 0.8 mm as measured by ultrasonography
- Negative pregnancy test for females
Exclusion
- Whole blood donation (greater than or equal to 450 ml) during the last three months before study start
- Unstable angina, congestive heart failure or uncontrolled hypertension
- Renal disease including nephrectomy and/or renal transplant
- Hepatic disease or abnormal liver function parameters
- Drug abuse or alcohol addiction
Key Trial Info
Start Date :
September 1 2002
Trial Type :
INTERVENTIONAL
End Date :
August 1 2005
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00185146
Start Date
September 1 2002
End Date
August 1 2005
Last Update
March 28 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Munich, Germany